Notice: This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends RTRX vs. PRGO, RYTM, APLS, MLTX, PTCT, AGIO, HCM, MRUS, XENE, and EWTXShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Perrigo (PRGO), Rhythm Pharmaceuticals (RYTM), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), PTC Therapeutics (PTCT), Agios Pharmaceuticals (AGIO), HUTCHMED (HCM), Merus (MRUS), Xenon Pharmaceuticals (XENE), and Edgewise Therapeutics (EWTX). These companies are all part of the "medical" sector. Travere Therapeutics vs. Perrigo Rhythm Pharmaceuticals Apellis Pharmaceuticals MoonLake Immunotherapeutics PTC Therapeutics Agios Pharmaceuticals HUTCHMED Merus Xenon Pharmaceuticals Edgewise Therapeutics Perrigo (NYSE:PRGO) and Travere Therapeutics (NASDAQ:RTRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Do institutionals & insiders have more ownership in PRGO or RTRX? 95.9% of Perrigo shares are owned by institutional investors. 0.7% of Perrigo shares are owned by company insiders. Comparatively, 4.6% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in PRGO or RTRX? Perrigo received 350 more outperform votes than Travere Therapeutics when rated by MarketBeat users. However, 73.17% of users gave Travere Therapeutics an outperform vote while only 66.67% of users gave Perrigo an outperform vote. CompanyUnderperformOutperformPerrigoOutperform Votes77066.67% Underperform Votes38533.33% Travere TherapeuticsOutperform Votes42073.17% Underperform Votes15426.83% Which has preferable earnings and valuation, PRGO or RTRX? Perrigo has higher revenue and earnings than Travere Therapeutics. Perrigo is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerrigo$4.66B0.79-$12.70M-$1.17-23.16Travere Therapeutics$175.34M5.32-$146.43M-$3.46-5.28 Which has more volatility and risk, PRGO or RTRX? Perrigo has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Is PRGO or RTRX more profitable? Perrigo has a net margin of -3.64% compared to Travere Therapeutics' net margin of -49.13%. Perrigo's return on equity of 7.38% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Perrigo-3.64% 7.38% 3.18% Travere Therapeutics -49.13%-36.38%-14.90% Does the media refer more to PRGO or RTRX? In the previous week, Perrigo had 7 more articles in the media than Travere Therapeutics. MarketBeat recorded 8 mentions for Perrigo and 1 mentions for Travere Therapeutics. Perrigo's average media sentiment score of 1.30 beat Travere Therapeutics' score of 0.00 indicating that Perrigo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend PRGO or RTRX? Perrigo presently has a consensus price target of $37.00, indicating a potential upside of 36.53%. Given Perrigo's stronger consensus rating and higher possible upside, analysts plainly believe Perrigo is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perrigo 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Travere Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPerrigo beats Travere Therapeutics on 13 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$932.21M$6.58B$5.14B$8.84BDividend YieldN/A8.11%5.05%4.07%P/E Ratio-8.6510.93132.3717.61Price / Sales5.32363.851,231.9986.52Price / CashN/A52.5940.0636.27Price / Book3.5510.176.956.36Net Income-$146.43M$153.36M$119.48M$226.00M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$18.26+2.2%N/A+197.3%$932.21M$175.34M-8.65221High Trading VolumePRGOPerrigo4.9833 of 5 stars$27.10-0.2%$37.00+36.5%-10.8%$3.70B$4.66B-23.169,140News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.1653 of 5 stars$59.27-0.2%$62.30+5.1%+78.0%$3.64B$77.43M-13.57140Analyst ForecastAPLSApellis Pharmaceuticals4.6238 of 5 stars$28.01+1.9%$49.94+78.3%-44.5%$3.48B$396.59M-13.38702Analyst ForecastMLTXMoonLake Immunotherapeutics3.2994 of 5 stars$51.86+4.1%$79.00+52.3%+16.8%$3.31BN/A-38.432PTCTPTC Therapeutics2.5632 of 5 stars$42.89+2.2%$42.00-2.1%+89.3%$3.31B$937.82M-7.061,410Analyst DowngradeAGIOAgios Pharmaceuticals3.3389 of 5 stars$55.54+1.7%$52.33-5.8%+154.0%$3.17B$26.82M4.89390HCMHUTCHMED1.1863 of 5 stars$17.70-1.4%$20.55+16.1%-3.1%$3.09B$838M0.001,988Analyst DowngradeNews CoverageMRUSMerus3.0125 of 5 stars$44.64+4.0%$85.45+91.5%+76.7%$3.06B$43.95M-11.1037Analyst ForecastNews CoverageGap UpXENEXenon Pharmaceuticals3.5287 of 5 stars$39.97+1.6%$57.45+43.7%+35.2%$3.05B$9.43M-13.95251Analyst RevisionEWTXEdgewise Therapeutics1.7412 of 5 stars$32.10+0.4%$38.40+19.6%+396.9%$3.04BN/A-21.4060 Related Companies and Tools Related Companies Perrigo Alternatives Rhythm Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives PTC Therapeutics Alternatives Agios Pharmaceuticals Alternatives HUTCHMED Alternatives Merus Alternatives Xenon Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RTRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
